



(51) International Patent Classification:

C07D 221/20 (2006.01) **A61K 31/438** (2006.01)
C07D 471/10 (2006.01) **A61P 3/10** (2006.01)

(21) International Application Number:

PCT/US2010/052126

(22) International Filing Date:

11 October 2010 (11.10.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/251,839 15 October 2009 (15.10.2009) US
 61/303,334 11 February 2010 (11.02.2010) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HAMDOUCHI, Chafiq** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **LINESWALA, Jayana, Pankaj** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **MAITI, Pranab** [IN/IN]; #96 Industrial Suburb, Second Phase, Yeswantpur Bangalore, Karnataka 560022 (IN).(74) Agents: **VORNDRAN-JONES, MaCharri** et al.; Eli Lilly and Company, Patent Division, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SPIROPIPERIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF FOR TREATING DIABETES



(57) Abstract: A compound of the formula:(I) or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.